Variation of brain natriuretic peptide and CK-MB levels in acute myocardial infarction patients after primary percutaneous coronary intervention

Objective To observe the safety of intravenous recombinant human brain natriuretic peptide (rhBNP) and variations of BNP and CK-MB levels in acute myocardial infarction (AMI) patients during and after primary pereutaneous coronary intervention (PCI). Methods Seventy AMI patients received standard drug therapy and primary PCI, were randomly divided into two groups. Group A received rhBNP 1.5 μg/kg intravenous injection in more than 3 minutes,then continuous infusion at 0. 01 μg·kg~(-1)·min~(-1) for 48 hours; Group B received saline infusion at the same rate as group A. During the infusion, the following side effects were observed: hypotention, headache, nausea, etc. Plasma BNP and CK-MB levels were measured pre-and post-PCI. Results (1) In group B, the peak concentration of plasma BNP was observed 24 hours post-PCI. Plasma BNP level was significant different 156 hours post-PCI between group A and group B (P=0. 023). (2) Subgroups analysis showed that serum CK-MB in group A was significantly decreased 60 hours post-PCI compared with that in group B (P0.05). (3) Serum BNP was positively correlated with age, sex (r=0. 522,P 0. 001; r=0. 303, P=0. 024), and negatively correlated with body weight, LVEF (r=-0. 504, P0. 001; r=- 0. 317,P=0. 032). (4) Fourteen patients presented with side effects during rhBNP infusion in group A, 16 patients in B group. There was no significant difference between 2 groups (P=0. 784). Conclusions Intravenous therapy of rhBNP in AMI patients recieved primary PCI was feasible and safe. Intravenous infusion of rhBNP during and after PCI might decrease cardiac injury.